Researchers looked at data from a previous study where 61 people with HIV and fatty liver disease were given either tesamorelin or a placebo, then focused on those taking integrase inhibitor drugs.

Scientific Claim

A randomized placebo-controlled trial involving 61 participants with HIV-associated non-alcoholic fatty liver disease was analyzed post-hoc to evaluate the effects of tesamorelin in individuals receiving integrase inhibitor therapy.

Original Statement

“To do this, we leveraged data from a previous placebo-controlled trial of 61 participants with HIV-associated NAFLD. Post-hoc analyses were performed to evaluate changes in body composition amongst individuals receiving INSTIs.”

From study:1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

This is a factual description of the study design, which is accurately stated without causal implications.

Evidence from Studies

Supporting (1)

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Randomized Controlled Trial

Human

Contradicting (0)

No contradicting evidence found

Source Study

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Score: 63

DOI: 10.1093/ofid/ofad500.1334

Similar Assertions

For people with HIV and fatty liver disease on INSTI drugs, tesamorelin likely reduces liver fat by 4.9% while placebo has almost no effect (0.1% decrease) after a year.

93%

For people with HIV and fatty liver disease on integrase inhibitors, taking tesamorelin for a year likely reduced liver fat by almost 5%, while the placebo group saw almost no change.

92%

People with HIV and fatty liver disease on INSTI drugs who took tesamorelin for a year likely saw their liver fat decrease by 31% compared to their starting point.

92%

For people with HIV and fatty liver disease on certain HIV drugs, taking tesamorelin for a year likely reduces belly fat by 8.3% while placebo makes it increase by 10.8%.

91%

For people with HIV and fatty liver disease who are taking integrase inhibitor drugs, taking tesamorelin for a year likely helped reduce belly fat, while those on a placebo saw their belly fat increase.

91%